Bloomberg Businessweek

A New Drug’s Delivery Problem

Zulresso, the first treatment for postpartum depression, is expensive and hard to administer

The world’s first drug for postpartum depression, Zulresso, cleared a major hurdle on March 19, when it won approval from the U.S. Food and Drug Administration. But even bigger challenges lie ahead for Sage Therapeutics Inc., the drug’s developer.

Zulresso, the brand name for brexanolone, works much faster to treat the condition than anything now available. Experts have hailed it as “groundbreaking,” a “game changer.” And postpartum depression affects as many as one in nine new mothers. These facts alone would suggest Zulresso is destined

You're reading a preview, sign up to read more.

More from Bloomberg Businessweek

Bloomberg Businessweek4 min readPolitics
Between A Rock And A Trade War
Gray concrete walls rise out of the Mediterranean off the coast of Haifa in northern Israel, part of what, by 2021, is supposed to be among the world’s most advanced class of seaports. The future shipping terminal, along with another being built fart
Bloomberg Businessweek10 min read
Pizza For The People
Fast-casual chain &Pizza wants to become the most progressive fast-food employer in the U.S.
Bloomberg Businessweek2 min read
The Poet Whose Lawsuit Couldn’t Stop the Party
Abiodun Oyewole v. Rita Ora et al. Case # 1:16-cv-01912 • In case you’re curious, here’s an excerpt of the lyrics from How We Do (Party): “I wanna party and bullshit … // ’Cause when the sun sets baby / On the avenue / I get that drunk sex feeling